Talampanel

CAS No. 161832-65-1

Talampanel ( GYKI-53773; LY-300164 )

Catalog No. M26835 CAS No. 161832-65-1

Talampanel is an orally and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor antagonist with anti-seizure activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 49 Get Quote
5MG 77 Get Quote
10MG 111 Get Quote
25MG 223 Get Quote
50MG 370 Get Quote
100MG 537 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Talampanel
  • Note
    Research use only, not for human use.
  • Brief Description
    Talampanel is an orally and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor antagonist with anti-seizure activity.
  • Description
    Talampanel is an orally and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor antagonist with anti-seizure activity. Talampanel (IVAX) has neuroprotective effects in rodent stroke models.(In Vivo):Talampanel (p.o.; 5 mg/kg; once a day; 2 weeks) decreases motoneuronal calcium in a mouse model of ALS .
  • Synonyms
    GYKI-53773; LY-300164
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    ASK1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    161832-65-1
  • Formula Weight
    337.4
  • Molecular Formula
    C19H19N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kawarazaki Y, Ichijo H, Naguro I. Apoptosis signal-regulating kinase 1 as a therapeutic target. Expert Opin Ther Targets. 2014 Jun;18(6):651-64.
molnova catalog
related products
  • Hinokitiol

    Hinokitiol (4-Isopropyltropolone;β-Thujaplicin) is a tropolone-related natural compound that can induces apoptosis and cell cycle arrest.

  • TAS6417

    TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC.

  • DCH36_06

    DCH36_06? as a bona fide is a potent p300/CBP inhibitor